Stephanie M Flaig1, Vincent H Gattone2, Bonnie L Blazer-Yost3. 1. Biology Department, Indiana University Purdue University Indianapolis, IN 46202, United States of America. 2. Department of Anatomy and Cell Biology, Indiana University School of Medicine, Indianapolis, IN 46202, United States of America. 3. Biology Department, Indiana University Purdue University Indianapolis, IN 46202, United States of America; Department of Anatomy and Cell Biology, Indiana University School of Medicine, Indianapolis, IN 46202, United States of America.
Abstract
BACKGROUND AND OBJECTIVES: The studies were designed to test the efficacy of two peroxisome proliferator-activated receptor γ (PPARγ) agonists in two rodent models of polycystic kidney disease (PKD). MATERIALS AND METHODS: The PCK rat is a slowly progressing cystic model while the Wpk-/- rat is a rapidly progressing model. PCK rats were fed with a pharmacological (0.4 mg/kg body weight [BW]) and a sub-pharmacological (0.04 mg/kg BW) dose of rosiglitazone (week 4-28). Wpk-/- rats were fed with pharmacological (2.0 mg/kg BW) and sub-pharmacologic (0.2 mg/kg BW) doses of pioglitazone from day 5 to 18. At termination, kidney weights of treated versus untreated cystic animals were used to determine efficacy. The current studies were also compared with previous studies containing higher doses of PPARγ agonists. The concentrations used in the animals were calculated with reference to equivalent human doses for both drugs. RESULTS: The current studies demonstrate: 1) that low, pharmacologically relevant, doses of the PPARγ agonists effectively inhibit cyst growth; 2) there is a class action of the drugs with both commercially available PPARγ agonists, rosiglitazone, and pioglitazone, inhibiting cyst growth; 3) the drugs showed efficacy in two different preclinical cystic models. In the PCK rat, animals fed with a sub-pharmacological dose of rosiglitazone for 24 weeks had significantly lower kidney weights than untreated animals (3.68 ± 0.13 g vs. 4.17 ± 0. 11 g, respectively, P < 0.01) while treatment with a pharmacologic dose had no significant effect on kidney weight. The rapidly progressing Wpk-/- rats were fed with pharmacological and sub-pharmacologic doses of pioglitazone from day 5 to 18 and the kidneys were compared with non-treated, cystic animals. Kidney weights on the pharmacologic dose were not statistically lower than the untreated animals while rats fed a sub-pharmacologic dose showed a significant decrease compared with untreated animals (3.35 ± 0.15 g vs. 4.55 ± 0.46 g, respectively, P = 0.045). CONCLUSION: Concentrations of PPARγ agonists below the human equivalent diabetic doses are effective in slowing cyst growth in two rodent models of PKD.
BACKGROUND AND OBJECTIVES: The studies were designed to test the efficacy of two peroxisome proliferator-activated receptor γ (PPARγ) agonists in two rodent models of polycystic kidney disease (PKD). MATERIALS AND METHODS: The PCKrat is a slowly progressing cystic model while the Wpk-/- rat is a rapidly progressing model. PCKrats were fed with a pharmacological (0.4 mg/kg body weight [BW]) and a sub-pharmacological (0.04 mg/kg BW) dose of rosiglitazone (week 4-28). Wpk-/- rats were fed with pharmacological (2.0 mg/kg BW) and sub-pharmacologic (0.2 mg/kg BW) doses of pioglitazone from day 5 to 18. At termination, kidney weights of treated versus untreated cystic animals were used to determine efficacy. The current studies were also compared with previous studies containing higher doses of PPARγ agonists. The concentrations used in the animals were calculated with reference to equivalent human doses for both drugs. RESULTS: The current studies demonstrate: 1) that low, pharmacologically relevant, doses of the PPARγ agonists effectively inhibit cyst growth; 2) there is a class action of the drugs with both commercially available PPARγ agonists, rosiglitazone, and pioglitazone, inhibiting cyst growth; 3) the drugs showed efficacy in two different preclinical cystic models. In the PCKrat, animals fed with a sub-pharmacological dose of rosiglitazone for 24 weeks had significantly lower kidney weights than untreated animals (3.68 ± 0.13 g vs. 4.17 ± 0. 11 g, respectively, P < 0.01) while treatment with a pharmacologic dose had no significant effect on kidney weight. The rapidly progressing Wpk-/- rats were fed with pharmacological and sub-pharmacologic doses of pioglitazone from day 5 to 18 and the kidneys were compared with non-treated, cystic animals. Kidney weights on the pharmacologic dose were not statistically lower than the untreated animals while rats fed a sub-pharmacologic dose showed a significant decrease compared with untreated animals (3.35 ± 0.15 g vs. 4.55 ± 0.46 g, respectively, P = 0.045). CONCLUSION: Concentrations of PPARγ agonists below the human equivalent diabetic doses are effective in slowing cyst growth in two rodent models of PKD.
Authors: Ursula M Smith; Mark Consugar; Louise J Tee; Brandy M McKee; Esther N Maina; Shelly Whelan; Neil V Morgan; Erin Goranson; Paul Gissen; Stacie Lilliquist; Irene A Aligianis; Christopher J Ward; Shanaz Pasha; Rachaneekorn Punyashthiti; Saghira Malik Sharif; Philip A Batman; Christopher P Bennett; C Geoffrey Woods; Carole McKeown; Martine Bucourt; Caroline A Miller; Phillip Cox; Lihadh Algazali; Richard C Trembath; Vicente E Torres; Tania Attie-Bitach; Deirdre A Kelly; Eamonn R Maher; Vincent H Gattone; Peter C Harris; Colin A Johnson Journal: Nat Genet Date: 2006-01-15 Impact factor: 38.330
Authors: Daisuke Yoshihara; Hiroki Kurahashi; Miwa Morita; Masanori Kugita; Yoshiyuki Hiki; Harold M Aukema; Tamio Yamaguchi; James P Calvet; Darren P Wallace; Shizuko Nagao Journal: Am J Physiol Renal Physiol Date: 2010-12-08
Authors: Jian Song; Mark A Knepper; Xinqun Hu; Joseph G Verbalis; Carolyn A Ecelbarger Journal: J Pharmacol Exp Ther Date: 2003-10-30 Impact factor: 4.030
Authors: Vincent H Gattone; Benjamin A Tourkow; Chad M Trambaugh; Alexander C Yu; Shelly Whelan; Carrie L Phillips; Peter C Harris; Richard G Peterson Journal: Anat Rec A Discov Mol Cell Evol Biol Date: 2004-04
Authors: Xiaofang Wang; Megan M Constans; Fouad T Chebib; Vicente E Torres; Lorenzo Pellegrini Journal: Am J Nephrol Date: 2019-05-22 Impact factor: 3.754
Authors: Anish A Kanhai; Hester Bange; Lotte Verburg; Kyra L Dijkstra; Leo S Price; Dorien J M Peters; Wouter N Leonhard Journal: Sci Rep Date: 2020-02-03 Impact factor: 4.379
Authors: Bonnie L Blazer-Yost; Robert L Bacallao; Bradley J Erickson; Michelle L LaPradd; Marie E Edwards; Nehal Sheth; Kim Swinney; Kristen M Ponsler-Sipes; Ranjani N Moorthi; Susan M Perkins; Vicente E Torres; Sharon M Moe Journal: Clin Kidney J Date: 2021-01-26